Table 5b: Correlation analysis (2).
Disadvantage |
Side effects |
Other drug |
Non compl |
How many |
Pyramid |
Sensit |
cerebel |
brainstem |
visual |
sphincter |
Other |
Knowl MS |
Physic |
Tv, internet |
Patients |
other |
> awaren |
> worries |
New ther |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Age |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gender |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Distance |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Primary school |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
High school |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Graduate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Married |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income 2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income 3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Avonex |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rebif |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Betaf/ext |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Copaxone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years dis |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Relapses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
> Severe |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
= Severe |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
< Severe |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
+ 5 years |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years of therapy |
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Disadvantages |
0.333* |
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Side effects |
0.098 |
0.293* |
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other drug |
0.447 |
0.149 |
-0.073 |
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non compl |
0.365* |
0.122 |
-0.178 |
0.816* |
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
How many |
0.135 |
0.135 |
0.197* |
0.100 |
0.000 |
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pyramid |
0.172 |
0.024 |
0.275* |
-0.163 |
-0.044 |
0.810* |
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Sensit |
0.480* |
0.222* |
-0.154 |
0.340* |
0.406* |
0.560* |
0.434* |
1 |
|
|
|
|
|
|
|
|
|
|
|
|
Cerebel |
-0.118 |
0.118 |
0.312* |
-0.476* |
-0.346* |
0.654* |
0.792* |
0.303* |
1 |
|
|
|
|
|
|
|
|
|
|
|
Brainstem |
-0.182 |
0.230* |
0.596* |
-0.298* |
-0.331* |
0.677* |
0.521* |
0.151 |
0.623* |
1 |
|
|
|
|
|
|
|
|
|
|
Visual |
0.029 |
0.243* |
0.223* |
0.065 |
0.231* |
0.611* |
0.655* |
0.337* |
0.508* |
0.490* |
1 |
|
|
|
|
|
|
|
|
|
Sphinct |
-0.152 |
0.096 |
0.007 |
0.154 |
0.428 |
0.065 |
0.086 |
0.181 |
0.142 |
0.148 |
0.550* |
1 |
|
|
|
|
|
|
|
|
Other |
-0.293* |
-0.098 |
0.048 |
-0.218* |
0.000 |
0.066 |
0.036 |
-0.086 |
0.312* |
0.195* |
0.0143 |
0.141 |
1 |
|
|
|
|
|
|
|
Knowl MS |
-0.163 |
-0.228* |
0.237* |
-0.073 |
-0.178 |
-0.153 |
-0.108 |
-0.246* |
0.035 |
-0.065 |
-0.385* |
0.007 |
0.429* |
1 |
|
|
|
|
|
|
Physicians |
-0.149 |
-0.149 |
-0.218* |
0.000 |
0.136 |
-0.201* |
-0.274* |
0.078 |
-0.053 |
-0.244* |
-0.239* |
0.216* |
0.655* |
0.364* |
1 |
|
|
|
|
|
Tv, internet |
0.200* |
0.067 |
0.228* |
-0.149 |
-0.122 |
0.404* |
0.368* |
0.152 |
0.450* |
0.545* |
0.224* |
-0.096 |
0.098 |
-0.293* |
-0.447* |
1 |
|
|
|
|
Patients |
0.200* |
0.067 |
-0.293* |
-0.149 |
-0.122 |
0.225* |
0.368 |
0.339* |
0.450* |
-0.230* |
0.068 |
-0.096 |
0.098 |
0.228* |
0.149 |
-0.067 |
1 |
|
|
|
Other |
-0.230* |
0.664* |
0.000 |
0.139 |
0.153 |
-0.040 |
-0.252* |
-0.156 |
-0.208* |
0.165 |
0.136 |
0.322* |
0.000 |
-0.119 |
-0.000 |
-0.221* |
-0.221 |
1 |
|
|
> Aware |
0.067 |
0.200* |
0.163 |
0.149 |
0.243* |
0.584* |
0.417* |
0.269* |
0.308* |
0.569* |
0.672* |
0.482* |
0.293* |
-0.098 |
0.149 |
0.333* |
-0.200* |
0.230* |
1 |
|
> Worrie |
0.683* |
0.228* |
-0.238* |
0.364* |
0.416* |
0.329* |
0.203* |
0.794* |
0.058 |
-0.029 |
0.157 |
-0.007 |
-0.048 |
-0.238* |
-0.073 |
0.293* |
0.293* |
-0.230 |
0.358* |
1 |
New ther |
* = significant at 95%